Salivary Gland Cancer Clinical Trial
— INDAGA-UKOfficial title:
Gene Expression Profiling in a Validation Cohort of Locally Advanced and Recurrent/Metastatic Salivary Gland Cancers: The INDAGA-UK Trial
The INDAGA-UK trial is a retrospective, multi-centre observational study in participants with locally advanced and recurrent salivary gland to investigate t its molecular profiling, and to explore new prognostic and druggable markers. We will analyse samples and data from patients diagnosed with salivary gland cancer from 2013 - 2023. Subject and sample identification will occur over a 12-month period. Samples and data will be analysed over the next 12 months prior to study end.
Status | Not yet recruiting |
Enrollment | 250 |
Est. completion date | January 31, 2026 |
Est. primary completion date | January 31, 2025 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Aged over 18 2. Histological diagnosis of salivary gland cancer (SGCs) 3. Availability of archival tissue (acceptable after 2013 up to present) 4. Ability to give informed consent (if applicable)* for retrieving histological specimen and preform molecular analysis *De-identified archival tissue from deceased patients will be collected as part of the study once REC approval is in place, if the patient was alive when the samples were taken and they are not part of the NHS opt out scheme. Exclusion Criteria: 1. Different H&N cancer of other histology 2. Thyroid cancers |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Royal Marsden NHS Foundation Trust |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | • Description of the molecular and genomic profile of locally advanced and recurrent-metastatic SGCs. | • Description of the molecular and genomic profile of locally advanced and recurrent-metastatic SGCs. | Time Frame: Through study completion, expected duration of 10 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03729297 -
Cabozantinib in Advanced Salivary Gland Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT01969578 -
Androgen Deprivation Therapy in Advanced Salivary Gland Cancer
|
Phase 2 | |
Completed |
NCT01703455 -
Activity of Sorafenib in Salivary Gland Cancer
|
Phase 2 | |
Recruiting |
NCT04140526 -
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05010629 -
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT03781986 -
APG-115 in Salivary Gland Cancer Trial
|
Phase 1/Phase 2 | |
Completed |
NCT03319641 -
PSMA-PET Imaging for Advanced ACC/SDC
|
N/A | |
Recruiting |
NCT02012699 -
Integrated Cancer Repository for Cancer Research
|
||
Recruiting |
NCT04028479 -
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
||
Recruiting |
NCT05483374 -
The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers
|
||
Completed |
NCT04291300 -
Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03172624 -
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
|
Phase 2 | |
Completed |
NCT00509002 -
Iressa Study in Patients With Salivary Gland Cancer
|
Phase 2 | |
Active, not recruiting |
NCT05008237 -
Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study
|
Phase 2 | |
Recruiting |
NCT03360890 -
Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
|
Phase 2 | |
Not yet recruiting |
NCT05898373 -
Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02069730 -
A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes
|
N/A | |
Recruiting |
NCT04209660 -
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
|
Phase 2 | |
Completed |
NCT01344356 -
Stereotactic Body Radiotherapy for Head and Neck Tumors
|
Phase 4 | |
Completed |
NCT03602079 -
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
|
Phase 1/Phase 2 |